share_log

Argus Research Initiates Coverage On Novo Nordisk With Buy Rating, Announces Price Target of $110

Benzinga ·  Oct 2, 2023 22:30

Argus Research analyst John Eade initiates coverage on Novo Nordisk (NYSE:NVO) with a Buy rating and announces Price Target of $110.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment